Interactive Investor
>>

MorphoSys AG ADR (NASDAQ:MOR) Share Price

MOR

MorphoSys AG ADR

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

 / 

- / -
-
- / -
-
-
-

NAV Price

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Loading...

Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development.

NASDAQ:MOR

US6177602025

USD

Loading...

Loading Comparison

Latest MOR News

Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News